GET DAILY SIGNALSEXEL vs INCY: +51% Momentum Edges +18% in Oncology Biotech Comparison
Key Takeaways
- EXEL (Exelixis) is a profitable oncology company with accelerating momentum, while INCY (Incyte) is a larger, diversified biopharmaceutical firm navigating a recent quarterly loss and pipeline transition.
- Tickeron AI Verdict: EXEL — driven by stronger trend consistency, profitability, and clearer near-term catalysts relative to INCY.
- EXEL shares have risen roughly 51% year to date, well ahead of INCY's roughly 18% advance, reflecting divergent momentum.
- INCY posted a 14% revenue increase in its latest quarter but swung to an adjusted loss tied to an acquisition, while EXEL delivered both revenue and earnings growth.
- For more on each company, explore EXEL Major News and EXEL Today's Price Move, as well as INCY Major News and INCY Today's Price Move.
- To see how automated strategies are currently positioned across the market, browse the Trending AI Robots page.
Two Oncology Names at Different Stages
Exelixis (EXEL) and Incyte (INCY) are two oncology-focused biopharmaceutical companies at different stages of their commercial lifecycles. Exelixis is a concentrated, profitable business built around a single flagship franchise, while Incyte operates a broader portfolio spanning hematology, oncology, and dermatology. Comparing these two names offers a useful lens on contrasting risk profiles, growth drivers, and market positioning. Growth-oriented traders may favor Exelixis' momentum and earnings stability, while investors seeking diversification and a deeper pipeline may find Incyte's scale compelling. This stock comparison examines recent performance, sentiment shifts, and the relative positioning of both tickers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Exelixis (EXEL): Focused Growth and Steady Execution
Exelixis (EXEL) is a biotechnology company focused on developing and commercializing cancer therapies. Its revenue engine is cabozantinib, sold as Cabometyx, which is approved for advanced renal cell carcinoma (RCC), previously treated hepatocellular carcinoma, and certain neuroendocrine tumors (NET). In recent weeks, the company reported quarterly revenue of roughly $659 million, up about 10% year over year, with adjusted earnings per share (EPS) of $0.94 that exceeded consensus estimates. Net product revenue growth was driven by higher volume and pricing for Cabometyx, whose prescription share in the oral tyrosine kinase inhibitor (TKI) market continued to climb.
Sentiment has been supported by steady franchise growth, disciplined capital allocation including an active share repurchase program, and a pipeline headlined by zanzalintinib, the company's next-generation therapy. That said, the regulatory review of zanzalintinib in colorectal cancer was extended, and management held full-year revenue guidance rather than raising it. Shares have outperformed the broader market in recent weeks, with a year-to-date gain of roughly 51%, reflecting strong relative momentum.
Incyte (INCY): Broader Portfolio with Near-Term Volatility
Incyte (INCY) is a global biopharmaceutical company with a diversified commercial portfolio. Its lead product, Jakafi (ruxolitinib), a JAK1/JAK2 inhibitor used for myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD), remains the largest single revenue contributor. The company also markets Opzelura cream for atopic dermatitis and vitiligo, as well as a growing hematology-oncology portfolio including Niktimvo, Zynyz, and Monjuvi/Minjuvi.
In recent market activity, Incyte reported quarterly revenue of about $1.56 billion, up 14% year over year, led by a 36% increase in Opzelura sales and strong growth across newer products. However, the company posted an adjusted net loss of $3.60 per share for the quarter, driven primarily by in-process research and development (IPR&D) expenses tied to its acquisition of Vega Therapeutics. Analysts have highlighted a credible path to growth beyond Jakafi, which faces loss of exclusivity near the end of the decade, while noting the company's expanding pipeline in myeloproliferative neoplasms and gastrointestinal oncology. Shares have risen roughly 18% year to date, a solid but more measured advance than EXEL. From what I see, checking Tickeron’s AI Trend Prediction Engine helped confirm the relative price trends here.
Head-to-Head: Concentration Versus Diversification
The two companies present a clear contrast in business model. Exelixis is highly concentrated, with the vast majority of revenue derived from a single molecule, cabozantinib. This focus produces strong margins and profitability but concentrates execution risk. Incyte, by contrast, is more diversified across products and indications, which reduces single-product risk but currently introduces earnings volatility, as evidenced by the recent quarterly loss tied to acquisition-related charges.
On growth drivers, Exelixis' near-term story hinges on Cabometyx volume growth and the eventual approval of zanzalintinib. Incyte's narrative rests on Opzelura momentum, newer hematology-oncology products, and a pipeline targeting high-incidence cancers. From a momentum standpoint, EXEL has demonstrated stronger relative performance, while INCY carries a larger market capitalization and broader revenue base. Risk factors also differ: Exelixis faces pipeline-timeline and concentration risk, whereas Incyte contends with the approaching loss of exclusivity on Jakafi and pipeline-dependent long-term growth. These trade-offs shape distinct market positioning for each ticker. One thing that stands out is how Tickeron’s AI Pattern Search Engine highlights these momentum differences.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, and relative positioning, Tickeron's AI would likely favor EXEL over INCY in the current environment. Exelixis combines profitability, a stronger recent price trend, and well-defined catalysts with disciplined capital returns, characteristics that typically align with favorable momentum signals. Incyte's broader diversification and deeper pipeline are meaningful long-term attributes, but its recent earnings volatility and heavier reliance on future pipeline execution introduce greater near-term uncertainty. This assessment is probabilistic and reflects current conditions rather than a definitive forecast of future returns. I’m watching this closely as conditions evolve.
Using AI Tools in Portfolio Analysis
In my regular research process, I turn to Tickeron’s AI Trading Bots to test how automated strategies might align with the momentum signals seen in names like these. The platform offers a range of bots with historical performance data across different market conditions, which helps me evaluate risk-adjusted approaches without relying solely on manual charting. It is not a substitute for fundamental work, but it adds a useful quantitative layer when comparing two stocks at different stages of growth.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EXEL's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for EXEL turned positive on October 09, 2026. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in 34 of 43 cases over the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on EXEL as a result. In 67 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in 206 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 166 of 268 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
EXEL broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 23 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.325) is normal, around the industry mean (3.162). P/E Ratio (21.091) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (6.305) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of small molecule therapies for the treatment of cancer
Industry Biotechnology
Advertisement